Table 1.
Clinicopathological characteristics of Neuroblastoma (NB) patients and post-chemotherapy tumor samples examined.
| Case | Age Months | Stage INSS | Therapy Protocol | MYCN Status | Del 1p | Del 11q | Gain 17q | Chemotherapy (Rapid COJEC) | Immunotherapy (Anti-GD2) | Response to Chemotherapy | Relapse | Overall Survival |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NB 1 | 66 | 3 | HR-NBL-1 | Amplified | Y | Y | Y | Y | N | Partial | Y | Dead of disease |
| NB 2 | 70 | 3 | HR-NBL-1 | Amplified | N | N | Y | Y | N | Partial | Y | Dead of disease |
| NB 3 | 178 | 3 | HR-NBL-1 | Amplified | N | Y | Y | Y | N | Partial | Y | Dead of disease |
| NB 4 | 80 | 3 | HR-NBL-1 | Amplified | Y | Y | Y | Y | N | Partial | Y | Dead of disease |
| NB 5 | 53 | 4 | HR-NBL-1 | Amplified | Y | N | Y | Y | N | Partial | Y | Dead of disease |
| NB 6 | 20 | 4 | HR-NBL-1 | Amplified | Y | N | Y | Y | Y | Partial | Y | Dead of disease |
| NB 7 | 37 | 3 | HR-NBL-1 | Amplified | Y | Y | Y | Y | N | Partial | Y | Dead of disease |
| NB 8 | 65 | 4 | HR-NBL-1 | Non-Amplified | N | N | Y | Y | Y | Partial | Y | Dead of disease |
| NB 9 | 63 | 4 | HR-NBL-1 | Non-Amplified | N | Y | Y | Y | N | Partial | N | Dead of disease |
| NB10 | 7 | 4 | HR-NBL-1 | Amplified | Y | N | Y | Y | N | Partial | Y | Dead of disease |
INSS = International Neuroblastoma Staging System; Y = yes; N = no; Del = Deletion; 1p, 11q, 17q = chromosomes arms affected by deletion or gain in NB.